-
Cobimetinib, sold
under the
brand name Cotellic, is an anti-cancer
medication used to
treat melanoma and
histiocytic neoplasms.
Cobimetinib is a MEK inhibitor...
-
dramatic efficacy in ECD
patients harboring the BRAF V600E mutation.
Cobimetinib, an oral
inhibitor of MEK1 and MEK2, was
approved in
November 2022. Other...
-
unresectable or
metastatic BRAF V600E or V600K mutation-positive melanoma.
Cobimetinib or XL518,
approved by US FDA in Nov 2015 for use in
combination with...
-
cycle of
cobimetinib and vemurafenib, parti****nts
received atezolizumab 840 mg
intravenous infusion every 2 w****s in
combination with
cobimetinib 60 mg...
- 2007, the
company partnered its MEK
inhibitor program with Genentech;
cobimetinib (at that time XL-518) was part of this collaboration.
Exelixis had filed...
-
Cellcept (mycophenolate mofetil), for
transplant rejection.
Cotellic (
cobimetinib), for melanoma.
Cymevene (ganciclovir), for
cytomegalovirus infection...
-
approved by the FDA.
Another similar combination is
vemurafenib and
cobimetinib.
Immunotherapy is also
starting to play an
important role in anaplastic...
-
planned including a
trial of
vemurafenib co-administered with GDC-0973 (
cobimetinib), a MEK-inhibitor.
After good
results in 2014, the
combination was submitted...
-
pulmonary fibrosis (IPF).
Developed by Intermune, Inc. 2015:
Cotellic (
cobimetinib): For use in
combination with
ZELBORAF (vemurafenib), to
treat metastatic...
- encorafenib, dabrafenib, and vemurafenib. Some MEK
inhibitors include cobimetinib, CI-1040, PD0325901,
binimetinib (MEK162), selumetinib, and trametinib...
